No Data
Express News | Maiwei Biotechnology has reached a strategic cooperation in the Peruvian market for the on-site administration of Shudankang injection.
Maiwei Biology-U (688062): Innovations in the pipeline steadily advancing, actively layout in the value gap.
The company released the third quarter report for 2024: the company's total operating revenue was 0.141 billion yuan, a year-on-year increase of 41.79%, net income attributable to shareholders was -0.694 billion yuan, a year-on-year decrease of 3.09%. Looking at quarterly data, the third quarter operations...
Maiwei Biotech: Maiwei Biotech Report for the Third Quarter of 2024
Maiwei Biotech Report for the Third Quarter of 2024
Express News | 193 companies were surveyed by institutions.
Financial report review U (688062): NECTIN-4 ADC demonstrates broad tumor potential, advancing registration clinical trials quickly.
Nectin-4 ADC is rapidly advancing in multiple indications. 9MW2821, the core product of Mabwell, is the fastest-developing domestic Nectin-4 ADC, targeting urothelial carcinoma (UC), cervical cancer.
No Data
No Data